Johnson & Johnson (NYSE:JNJ) Stake Decreased by Lakeside Advisors INC.

Lakeside Advisors INC. cut its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,077 shares of the company’s stock after selling 529 shares during the quarter. Johnson & Johnson accounts for 3.6% of Lakeside Advisors INC.’s portfolio, making the stock its 8th biggest holding. Lakeside Advisors INC.’s holdings in Johnson & Johnson were worth $4,430,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. Bell Investment Advisors Inc increased its stake in Johnson & Johnson by 77.0% in the fourth quarter. Bell Investment Advisors Inc now owns 1,131 shares of the company’s stock valued at $200,000 after purchasing an additional 492 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its stake in Johnson & Johnson by 11.0% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 512,313 shares of the company’s stock valued at $90,500,000 after purchasing an additional 50,834 shares during the last quarter. Nixon Peabody Trust Co. acquired a new position in Johnson & Johnson in the fourth quarter valued at $290,000. Moreno Evelyn V increased its stake in Johnson & Johnson by 101.4% in the fourth quarter. Moreno Evelyn V now owns 5,976 shares of the company’s stock valued at $1,056,000 after purchasing an additional 3,009 shares during the last quarter. Finally, Cohen Lawrence B increased its stake in Johnson & Johnson by 74.9% in the fourth quarter. Cohen Lawrence B now owns 5,001 shares of the company’s stock valued at $883,000 after purchasing an additional 2,142 shares during the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on JNJ. Piper Sandler dropped their target price on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Raymond James decreased their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. SVB Leerink decreased their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Guggenheim started coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price for the company. Finally, UBS Group started coverage on Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

Insider Buying and Selling at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $159.34 on Wednesday. The stock has a fifty day moving average price of $159.29 and a two-hundred day moving average price of $166.49. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The firm has a market cap of $414.08 billion, a P/E ratio of 33.33, a PEG ratio of 2.74 and a beta of 0.53. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period last year, the company posted $2.67 EPS. Research analysts forecast that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a yield of 2.99%. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.